Mirae Asset Venture Investment — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundPfizer VenturesPolaris PartnersTaiho Ventures, LLC
GamingBrooklyn, US
Co-investorsTechstarsB3 CapitalEQUIAMLightning CapitalMighty CapitalQuest Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.